Last reviewed · How we verify
Shanchol vaccine — Competitive Intelligence Brief
phase 3
Oral inactivated vaccine
Vibrio cholerae O1 and O139 antigens; cholera toxin B subunit
Infectious Disease / Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Shanchol vaccine (Shanchol vaccine) — International Centre for Diarrhoeal Disease Research, Bangladesh. Shanchol is an oral, inactivated cholera vaccine that stimulates immune responses against Vibrio cholerae O1 and O139 antigens to prevent cholera infection.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Shanchol vaccine TARGET | Shanchol vaccine | International Centre for Diarrhoeal Disease Research, Bangladesh | phase 3 | Oral inactivated vaccine | Vibrio cholerae O1 and O139 antigens; cholera toxin B subunit |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Oral inactivated vaccine class)
- International Centre for Diarrhoeal Disease Research, Bangladesh · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Shanchol vaccine CI watch — RSS
- Shanchol vaccine CI watch — Atom
- Shanchol vaccine CI watch — JSON
- Shanchol vaccine alone — RSS
- Whole Oral inactivated vaccine class — RSS
Cite this brief
Drug Landscape (2026). Shanchol vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/shanchol-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab